Finally, the cumulative rates of HCC development in patients with EOT-AFP ≥5.3 and <5.3 ng/mL were 4.3% and 0.2%, respectively, at one year, 5.2% and 0.9% at two years, 9.4% and 1.9% at three years, and 12.8% and 2.4% at four years (Fig 5B). Here, AFP is linked to hepatocellular carcinoma.